12 Month Price Forecast For ACHV
Distance to ACHV Price Forecasts
ACHV Price Momentum
🤔 Considering Achieve Life Sciences (ACHV)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 1:43 PM UTC
ACHV Analyst Ratings & Price Targets
Based on our analysis of 8 Wall Street analysts, ACHV has a consensus that is bullish. The median price target is $14.00, with forecasts ranging from $10.00 to $30.00. Currently, there are 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With ACHV currently trading at $2.85, the median price forecast suggests a 391.2% upside. The most optimistic forecast comes from at , projecting a 952.6% upside, while at provides the most conservative target, suggesting a 250.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACHV Analyst Consensus
ACHV Price Target Range
Latest ACHV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACHV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $12.00 |
| Sep 27, 2024 | Raymond James | Gary Nachman | Strong Buy | Initiates | $20.00 |
| Aug 15, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $11.00 |
| May 13, 2024 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $11.00 |
| Apr 17, 2024 | JonesTrading | Justin Walsh | Buy | Initiates | $20.00 |
| Apr 1, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $18.00 |
| Mar 5, 2024 | Lake Street | Thomas Flaten | Buy | Maintains | $11.00 |
| Dec 12, 2023 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $18.00 |
| Jun 1, 2023 | Lake Street | Buy | Maintains | $0.00 | |
| May 31, 2023 | Lake Street | Thomas Flaten | Buy | Maintains | $19.00 |
| May 10, 2023 | Lake Street | Thomas Flaten | Buy | Maintains | $22.00 |
| Mar 17, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $17.00 |
| Nov 16, 2022 | Maxim Group | Jason McCarthy | Buy | Maintains | $8.00 |
| Oct 4, 2021 | Alliance Global Partners | James Molloy | Buy | Initiates | $25.00 |
| Jun 23, 2021 | Oppenheimer | Outperform | Initiates | $0.00 | |
| Nov 25, 2020 | Maxim Group | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Lake Street | Buy | Initiates | $0.00 | |
| Sep 17, 2020 | Lake Street | Buy | Initiates | $0.00 | |
| Feb 25, 2020 | HC Wainwright& Co. | Buy | Initiates | $0.00 |
Stocks Similar to Achieve Life Sciences Inc
The following stocks are similar to Achieve Life Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Achieve Life Sciences Inc (ACHV) Financial Data
Achieve Life Sciences Inc has a market capitalization of $106.26M with a P/E ratio of -1.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -186.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Achieve Life Sciences Inc (ACHV) Company Overview
About Achieve Life Sciences Inc
Develops smoking cessation pharmaceuticals.
The company operates as a clinical-stage pharmaceutical entity focused on developing and commercializing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction. It generates revenue through licensing and supply agreements, such as its partnership with Sopharma AD and the University of Bristol, which support its research and development efforts.
Achieve Life Sciences, Inc. is based in Vancouver, Canada, positioning itself in the growing market for smoking cessation products. As a clinical-stage company, it is at the forefront of innovation in nicotine addiction treatment, which could attract significant interest from investors looking for opportunities in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
22
CEO
Dr. Richard A. B. Stewart
Country
Canada
IPO Year
1995
Website
www.achievelifesciences.comAchieve Life Sciences Inc (ACHV) Latest News & Analysis
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
12 days agoNew directors with significant leadership experience in corporate strategy and commercialization have joined the company, potentially enhancing its strategic direction and market approach.
New directors with strong leadership in corporate strategy and commercialization may enhance company growth prospects, influencing stock performance and investor confidence.
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
16 days agoAchieve Life Sciences, Inc. (Nasdaq: ACHV) will host one-on-one meetings during the J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025, focusing on cytisinicline for nicotine dependence.
Achieve Life Sciences is actively engaging with investors at a major healthcare conference, signaling potential growth and interest in its nicotine dependence treatment, which may impact stock performance.
Over 300 participants have completed six months of Cytisinicline treatment in the ORCA-OL trial, fulfilling the long-term exposure requirement for a New Drug Application submission.
Completion of the ORCA-OL Trial with over 300 participants indicates progress towards NDA submission for Cytisinicline, potentially boosting the company's stock value and market confidence.
Achieve Life Sciences appointed Mark Oki as CFO, effective December 5, 2024. He will manage financial strategy and operations, supporting the company's focus on nicotine dependence treatment.
The appointment of a new CFO signals potential strategic shifts and financial oversight, impacting investor confidence and the company's direction in drug commercialization.
Milestone highlights Cytisinicline's potential as a novel treatment for vaping cessation, indicating promising developments in the pharmaceutical sector.
Cytisinicline's potential as a first-in-class vaping cessation treatment could disrupt the smoking cessation market, impacting pharmaceutical investments and growth opportunities.
The report provides comprehensive coverage of pipeline drug profiles, detailing clinical and nonclinical products, therapeutic assessments by type, stage, administration route, and molecule type.
The detailed pipeline drug profiles indicate potential future revenue streams for pharmaceutical companies, influencing stock valuations and investment strategies in the biotech sector.
Frequently Asked Questions About ACHV Stock
What is Achieve Life Sciences Inc's (ACHV) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Achieve Life Sciences Inc (ACHV) has a median price target of $14.00. The highest price target is $30.00 and the lowest is $10.00.
Is ACHV stock a good investment in 2025?
According to current analyst ratings, ACHV has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ACHV stock?
Wall Street analysts predict ACHV stock could reach $14.00 in the next 12 months. This represents a 391.2% increase from the current price of $2.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Achieve Life Sciences Inc's business model?
The company operates as a clinical-stage pharmaceutical entity focused on developing and commercializing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction. It generates revenue through licensing and supply agreements, such as its partnership with Sopharma AD and the University of Bristol, which support its research and development efforts.
What is the highest forecasted price for ACHV Achieve Life Sciences Inc?
The highest price target for ACHV is $30.00 from at , which represents a 952.6% increase from the current price of $2.85.
What is the lowest forecasted price for ACHV Achieve Life Sciences Inc?
The lowest price target for ACHV is $10.00 from at , which represents a 250.9% increase from the current price of $2.85.
What is the overall ACHV consensus from analysts for Achieve Life Sciences Inc?
The overall analyst consensus for ACHV is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are ACHV stock price projections?
Stock price projections, including those for Achieve Life Sciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
